NEJM Journal Watch - Home | Facebook
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
NEJM on Twitter: "The POLO trial evaluated the efficacy of maintenance therapy with olaparib in patients with a germline BRCA mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based
GI SLIDE DECK 2019 Selected abstracts from: - ppt download
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Albumin Replacement in Patients with Severe Sepsis or Septic Shock
Update: What is new in targeted therapy for pancreatic cancer? - YouTube
Nejmoa 2206038 - NEJM - ####### T h e n e w e n g l a n d j o u r n a l o f m e d i c i n e n engl j - Studocu
Periodici elettronici - Accesso in trial a NEJM sul sito dell'editore fino al 14 giugno 2021 - Centro Servizi Bibliotecari
Dr. Andrew Hendifar (@DrHendifar) / Twitter
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POL
GI SLIDE DECK 2019 Selected abstracts from: - ppt download
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Diapositiva 1
NEJM Journal Watch - Postitused | Facebook
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Novel and Emerging Therapeutic Strategies in the Management of Select Gastrointestinal Cancers Wells A Messersmith, MD Professor and Head, Division of. - ppt download
POLO Trial - The ASCO Post
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
